UCB SA (UCB) - Financial and Strategic SWOT Analysis Review

  • ID: 4302706
  • SWOT Analysis
  • 55 pages
  • GlobalData
  • UCB (Union chimique belge)
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Biotie Therapies Corp
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • MORE
UCB SA (UCB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities - A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

UCB SA (UCB) is a biopharmaceutical company that discovers and develops novel medicines and solutions to help treat various diseases. It focuses mainly on products for the treatment of central nervous system (CNS) and immunology related conditions. The company's key medicines include Cimzia for ankylosing spondylitis, axial spondylarthritis, Crohn's disease, psoriatic arthritis and rheumatoid arthritis; Neupro for Parkinson's disease and Restless legs syndrome; and Vimpat, Keppra and Briviact for epilepsy. UCB is also developing new therapies for neurological and immunological diseases. The company operates subsidiaries in the US, Japan, China, Germany, Italy, Spain, France, the UK, Ireland, Belgium, Brazil, Russia, India, Mexico, Turkey and other countries. UCB is headquartered in Brussels, Belgium.

UCB SA Key Recent Developments

Apr 26,2017: UCB Selects Medidata Clinical Cloud to Support Patient-Centric Drug Development
Apr 24,2017: UCB First Three Months Interim Report 2017: UCB with a good start into 2017
Mar 24,2017: UCB General Meeting on 27 April 2017
Dec 15,2016: New appointments on UCB's Board of Directors
Oct 28,2016: UCB announces availability of prefilled pen for rheumatic diseases

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • AstraZeneca Plc
  • Biotie Therapies Corp
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Johnson & Johnson
  • MORE
Section 1 - About the Company
UCB SA - Key Facts
UCB SA - Key Employees
UCB SA - Key Employee Biographies
UCB SA - Major Products and Services
UCB SA - Pharmaceutical Pipeline Products Data
UCB SA, Pipeline Products by Therapy Area
UCB SA, Pipeline Products by Development Phase
UCB SA - History
UCB SA - Company Statement
UCB SA - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

Section 2 - Company Analysis
UCB SA - Business Description
UCB SA - Corporate Strategy
UCB SA - SWOT Analysis
SWOT Analysis - Overview
UCB SA - Strengths
UCB SA - Weaknesses
UCB SA - Opportunities
UCB SA - Threats
UCB SA - Key Competitors

Section 3 - Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
UCB SA, Recent Deals Summary

Section 5 - Company’s Recent Developments
Apr 26, 2017: UCB Selects Medidata Clinical Cloud to Support Patient-Centric Drug Development
Apr 24, 2017: UCB First Three Months Interim Report 2017: UCB with a good start into 2017
Mar 24, 2017: UCB General Meeting on 27 April 2017
Dec 15, 2016: New appointments on UCB's Board of Directors
Oct 28, 2016: UCB announces availability of prefilled pen for rheumatic diseases
Sep 13, 2016: Neuropore Therapies Announces Achievement of Key Program Milestone
Jul 27, 2016: UCB continues to deliver on its growth strategy
Apr 25, 2016: UCB First Three Months Interim Report 2016
Apr 21, 2016: UCB underlines its commitment to improving the lives of people with Parkinson’s to mark UK’s Parkinson’s Awareness Week
Apr 04, 2016: IXICO Joins Global Parkinson’s Consortium

Section 6 - Appendix
Methodology
Ratio Definitions

List of Tables
UCB SA, Key Facts
UCB SA, Key Employees
UCB SA, Key Employee Biographies
UCB SA, Major Products and Services
UCB SA, Number of Pipeline Products by Therapy Area
UCB SA, Number of Pipeline Products by Development Stage
UCB SA, History
UCB SA, Subsidiaries
UCB SA, Joint Venture
UCB SA, Key Competitors
UCB SA, Ratios based on current share price
UCB SA, Annual Ratios
UCB SA, Annual Ratios (Cont...1)
UCB SA, Annual Ratios (Cont...2)
UCB SA, Interim Ratios
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
UCB SA, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017
UCB SA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
UCB SA, Pipeline Products by Therapy Area
UCB SA, Pipeline Products by Development Phase
UCB SA, Performance Chart (2012 - 2016)
UCB SA, Ratio Charts
UCB SA, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017
UCB SA, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Valeant Pharmaceuticals International Inc
  • Servier Laboratories Ltd
  • Novartis AG
  • Merck Serono SA
  • Johnson & Johnson
  • GlaxoSmithKline Plc
  • Eli Lilly and Company
  • Biotie Therapies Corp
  • AstraZeneca Plc
  • Amgen Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll